Santagata Davide: Thrombin Generation and Comparative Anticoagulant Pharmacodynamics
Santagata Davide, Resident Doctor at University of Insubria, shared Joseph R. Shaw’s post on LinkedIn, adding:
”A highly insightful review on thrombin generation as a framework for understanding the pharmacodynamics of oral anticoagulants—and why anticoagulants with apparently similar clinical purposes can produce markedly different effects on the coagulation system.
Particularly interesting implications for DOACs, VKAs, and emerging FXI inhibitors. A valuable read for anyone working in thrombosis and hemostasis.”
Joseph R. Shaw, Hematologist (Thrombosis and Anticoagulation Specialist) at The Ottawa Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Pharmacology and Therapeutics, adding:
”I am very happy to share our new review, ‘Thrombin generation and the pharmacodynamics of oral anticoagulants,’ published in Pharmacology and Therapeutics – one of the ten most-cited journals in pharmacology.
From a pharmacodynamic perspective, not all anticoagulants are the same. Drug levels and conventional clotting assays are useful, but do not fully describe how anticoagulants differentially impact thrombin generation.
Blocking coagulation factors near coagulation’s fulcrum, particularly prothrombinase or thrombin, is less susceptible to redundancy. Multitarget inhibition, on the other hand, disrupts the entire system. Pharmacodynamic potency therefore reflects not only binding affinity or reversibility for a primary target, but also its positional leverage within the network and the number of convergent points it engages.
We use thrombin generation as a common language for comparative anticoagulant pharmacology. Broader-acting agents such as VKAs and UFH achieve deeper, cumulative suppression. The tradeoff familiar to clinicians is pharmacokinetic fragility and, on average, less consistency. Direct inhibitors provide greater pharmacodynamic consistency despite increasingly recognized variability in drug levels within and between patients.
These differences may help explain why broader-acting anticoagulants better preserve antithrombotic efficacy in highly prothrombotic settings, mechanical heart valves, antiphospholipid syndrome, rheumatic mitral stenosis, and catheter-associated thrombosis. The same deeper suppression may also help explain the higher intracranial hemorrhage risk with VKAs versus DOACs.
These signatures may help model molecular pharmacology’s effects on coagulation and better account for pharmacological contributions to bleeding and breakthrough thrombosis, even when drug concentrations appear ‘on target.’
The review builds on and expands the framework we recently proposed for parenteral anticoagulants in Pharmacological Reviews:
We extend this framework across oral classes, with implications for how we perceive anticoagulants and how factor XI inhibitors fit within the current therapeutic landscape.
We hope it will be a useful reference for comparative anticoagulant pharmacology over the next decade.”
Title: Thrombin generation and the pharmacodynamics of oral anticoagulants
Authors: Joseph R. Shaw, Dylan Burger, Julie Vassart, Michael Hardy, Lana A. Castellucci, Marc Carrier, Paul Y. Kim, Jonathan Douxfils, Francois Mullier, Bianca Rocca, Jean M. Connors, Henri Spronk, Jerrold H. Levy, Hugo ten Cate
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 27, 2026, 16:37Chris Baugh: Stabilize Measure Decide Managing Residual FXa Inhibitor Effects in Urgent Care
-
Aug 27, 2026, 16:26Aurelio Maggio: New Perspectives in The Treatment of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 27, 2026, 16:24Bruno Pougault : Refrigerated Platelets Could Transform Hemorrhage Management
-
Aug 27, 2026, 16:20Women’s Equality and the Fight for Equitable Healthcare – Hemophilia Federation of America
-
Aug 27, 2026, 16:16Thomas Georgas: HIT Requires More Than a Platelet Count
-
Aug 27, 2026, 15:59Leslie Iverson: What Does a Zero CAC Score Really Mean?
-
Aug 27, 2026, 15:42Shahram Raza Shouq: Small Steps Toward a Thalassaemia-Free Future
-
Aug 27, 2026, 15:27Dai H. Chung: A New Foundation for Studying Pediatric Pulmonary Embolism
-
Aug 27, 2026, 15:10David McIntosh: The World Needs More Blood Collectors, Not Just More Donors